Discover more insights into Programmed Death 프로그래밍된 죽음

Programmed Death sentence examples within immune checkpoint inhibitor



Immune checkpoint inhibitor toxicity: A new indication for therapeutic plasma exchange?


Extra-Nodal, Nasal, Natural Killer T-Cell Lymphoma Treated With a Checkpoint Inhibitor: A Case Report of a Sustained Complete Response

Programmed Death sentence examples within programmed cell death



Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) gene expression in primary breast cancer


Programmed Cell Death-Ligand 1 (PD-L1) gene Single Nucleotide Polymorphism in Graves’ Disease and Hashimoto’s Thyroiditis in Korean Patients

Programmed Death sentence examples within non small cell



Persistent Response and Prolonged Survival Following Pembrolizumab Discontinuation Due to Long-Lasting Autoimmune Colitis in Advanced NSCLC: A Case Report


First-Line Nivolumab Plus Ipilimumab vs Chemotherapy in Advanced Non-Small Cell Lung Cancer With Tumor PD-L1 ≥ 1%: Patient-Reported Outcomes From CheckMate 227 Part 1.



Programmed Death sentence examples within lymphocyte associated protein



T follicular helper cells: linking cancer immunotherapy and immune-related adverse events


MiRNA-based model for predicting the TMB level in colon adenocarcinoma based on a LASSO logistic regression method

Programmed Death sentence examples within ligand 1 expression



PD-L1 expression in megakaryocytes and its clinicopathological features in primary myelofibrosis patients.


Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma.

Programmed Death sentence examples within advanced non small



Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study


Programmed Death Ligand 1 (PD-L1) Expression and its Association with Clinicopathologic Profile in Patients with Non-Small Cell Lung Cancer in a Philippine Tertiary Medical Center

Programmed Death sentence examples within epidermal growth factor



EGFR mutation status in non-small cell lung cancer receiving PD-1/PD-L1 inhibitors and its correlation with PD-L1 expression: a meta-analysis


Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP)

Programmed Death sentence examples within tumor mutational burden



[Blood-based Biomarkers in the Immune Checkpoint Inhibitor Treatment in 
Non-small Cell Lung Cancer].


Dramatic Response to Pembrolizumab Monotherapy in a Patient With ARID1A-Mutant Lung Adenocarcinoma: Case Report.

Programmed Death sentence examples within tumor infiltrating lymphocyte



Immune-related biomarkers in triple-negative breast cancer


Noninvasive evaluation of tumor immune microenvironment in patients with clear cell renal cell carcinoma using metabolic parameter from preoperative 2-[18F]FDG PET/CT

Programmed Death sentence examples within lymphocyte antigen 4



Effects of a Unique Combination of the Whole-Body Low Dose Radiotherapy with Inactivation of Two Immune Checkpoints and/or a Heat Shock Protein on the Transplantable Lung Cancer in Mice


Expression of immune checkpoint molecules in Iraqi acute myeloid leukemia patients

Programmed Death sentence examples within anti programmed cell



Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma


Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and α-PD-1.

Programmed Death sentence examples within lymphocyte associated antigen



Systematic review of combinations of targeted or immunotherapy in advanced solid tumors


Combined immune checkpoint inhibitors of CTLA4 and PD-1 for hepatic melanoma of unknown primary origin: A case report

Programmed Death sentence examples within receptor ligand 1



Прогностические биомаркеры эффективности иммунотерапии злокачественных новообразований ингибиторами контрольных точек иммунного ответа


Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study

Programmed Death sentence examples within immune checkpoint molecule



KPNB1 Inhibitor Importazole Reduces Ionizing Radiation-Increased Cell Surface PD-L1 Expression by Modulating Expression and Nuclear Import of IRF1.


N6-Methyladenosine-Related lncRNAs As Potential Biomarkers For Predicting The Prognoses And Immune Responses In Patients With Cervical Cancer

Programmed Death sentence examples within transforming growth factor



T-Cell-Derived Nanovesicles for Cancer Immunotherapy.


Intestinal cDC1 drive cross-tolerance to epithelial-derived antigen via induction of FoxP3+CD8+ Tregs

Programmed Death sentence examples within 1 ligand 1



Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05


Alveolar Macrophages Inherently Express Programmed Death-1 Ligand 1 for Optimal Protective Immunity and Tolerance

Programmed Death sentence examples within immune checkpoint protein



Relationship between PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Canine Mammary Tumor


A snapshot of the PD-1/PD-L1 pathway

Programmed Death sentence examples within ligand 1 inhibitor



Chemotherapy plus atezolizumab for a patient with small cell lung cancer undergoing hemodialysis: A short report


Double the Battle: Two Cases of Irreversible Endocrinopathies in Patients Already Fighting Metastatic Cancer

Programmed Death sentence examples within ligand 1 antibody



SHR‐1316, an anti‐PD‐L1 antibody, plus chemotherapy as the first‐line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study


Improving Image-Guided Surgical and Immunological Tumor Treatment Efficacy by Photothermal and Photodynamic Therapies Based on a Multifunctional NIR AIEgen.

Programmed Death sentence examples within 1 programmed cell



Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer


ATM/NEMO signaling modulates the expression of PD-L1 following docetaxel chemotherapy in prostate cancer

Programmed Death sentence examples within 1 immune checkpoint



Lenvatinib plus Anti-PD-1 Combination Therapy for Advanced Cancers: Defining Mechanisms of Resistance in an Inducible Transgenic Model of Thyroid Cancer.


Ovarian cancer: new strategies and emerging targets for the treatment of patients with advanced disease

Programmed Death sentence examples within immune checkpoint blockade



Renal Clearable Ultrasmall Single-Crystal Fe Nanoparticles for Highly Selective and Effective Ferroptosis Therapy and Immunotherapy.


Microbiota modulation to fight cancer

Programmed Death sentence examples within neck squamous cell



Immune Checkpoint Inhibitors Regulate K+ Channel Activity in Cytotoxic T Lymphocytes of Head and Neck Cancer Patients


CMTM4 regulates epithelial–mesenchymal transition and PD‐L1 expression in head and neck squamous cell carcinoma

Programmed Death sentence examples within combined positive score



PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy.


Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody

Programmed Death sentence examples within 1 monoclonal antibody



Coexistence of oral mucous membrane pemphigoid and lichenoid drug reaction: a case of toripalimab-triggered and pembrolizumab-aggravated oral adverse events.


Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis

Programmed Death sentence examples within tumor proportion score



Dramatic, significant metabolic response to a one-time pembrolizumab treatment following a relapse of pre-existing organizing pneumonia in a patient with advanced non-small cell lung cancer: A case report.


Rapid-onset and fatal pneumonitis from trametinib treatment of non-small cell lung cancer: A case report

Programmed Death sentence examples within progression free survival



Immunotherapy in Triple-Negative Breast Cancer.


Associations between peripheral blood lymphocyte subsets and clinical outcomes in patients with lung cancer treated with immune checkpoint inhibitor.

Programmed Death sentence examples within immune related adverse



Relapsing polychondritis after treatment with PD-1 blockade


Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy.

Programmed Death sentence examples within tumor immune microenvironment



A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes


Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer

Programmed Death sentence examples within tyrosine kinase inhibitor



Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world.


The predictive and prognostic effects of PD-L1 expression on TKI treatment and survival of EGFR-mutant NSCLC

Programmed Death sentence examples within squamous cell carcinoma



Case Report: Autoimmune Pemphigus Vulgaris in a Patient Treated With Cemiplimab for Multiple Locally Advanced Cutaneous Squamous Cell Carcinoma


Distinct prognostic values of programmed death-ligand 1 and programmed cell death protein 1 in lung adenocarcinoma and squamous cell carcinoma patients.

Programmed Death sentence examples within lymphocyte activation gene



The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3


Immune profiling of pituitary tumors reveals variations in immune infiltration and checkpoint molecule expression

Programmed Death sentence examples within human epidermal growth



Construction of a full-length antibody phage display vector.


Current therapeutic options for gastric adenocarcinoma

Programmed Death sentence examples within tumor mutation burden



Recurrent undifferentiated embryonal sarcoma of the liver in adult patient treated by pembrolizumab: A case report


A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab

Programmed Death sentence examples within ligand 1 monoclonal



Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model


Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program

Programmed Death sentence examples within ligand 1 positive



Durable response after discontinuation of pembrolizumab therapy for intrahepatic cholangiocarcinoma: a case report


KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma.

Programmed Death sentence examples within esophageal squamous cell



Nomograms Predicting Response and Survival of Esophageal Squamous Cell Carcinoma Patients Treated With Anti-PD-1 Therapy.


The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma.

Programmed Death sentence examples within first line treatment



[A Real-world Study on the Assessment of Pathological Characteristics and Targeted Therapeutic Effect of Non-small Cell Lung Cancer Patients with Positive Driving Genes and High PD-L1 Expression].


Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy.

Programmed Death sentence examples within monoclonal antibodies targeting



[Management of toxicities from immunotherapy].


PD-L1 in Cytological Samples: A Review and a Practical Approach

Programmed Death sentence examples within vascular endothelial growth



Antitumor Effects of Ursolic Acid through Mediating the Inhibition of STAT3/PD-L1 Signaling in Non-Small Cell Lung Cancer Cells


Biomarker Evidence of the Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS) in Chronic Critical Illness (CCI) After Surgical Sepsis.

Programmed Death sentence examples within immune checkpoint inhibition



Outlook into the future of front-line immune checkpoint inhibition in metastatic urothelial carcinoma


Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT).

Programmed Death sentence examples within immune checkpoint therapy



P31.01 A False Alarm of COVID-19 Pneumonia in Lung Cancer: A Case Report of Anti-PD-1 Related Pneumonitis


P31.02 WITHDRAWN

Programmed Death sentence examples within triple negative breast



Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.


Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients

Programmed Death sentence examples within protein ligand 1



Safety and efficacy of anti-PD-1 inhibitors in Chinese patients with advanced lung cancer and hepatitis B virus infection: a retrospective single-center study.


Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities.

Programmed Death sentence examples within humanized monoclonal antibody



Dostarlimab: First Approval


Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial.

Programmed Death sentence examples within tumor infiltrating immune



Prognostic Role of Programmed Death Ligand-1 on Tumor-Infiltrating Immune Cells in “High-Risk” Patients Following Radical Cystectomy: A Retrospective Cohort Study


Untangling Triple-Negative Breast Cancer Molecular Peculiarity and Chemo-Resistance: Trailing Towards Marker-Based Targeted Therapies

Programmed Death sentence examples within renal cell carcinoma



Autophagy controls programmed death-ligand 1 expression on cancer cells (Review).


PD-L1 Expression and Clinicopathological Factors in Renal Cell Carcinoma: A Comparison of Antibody Clone 73-10 With Clone 28-8

Programmed Death sentence examples within indoleamine 23 dioxygenase



Characterization of immune infiltration in sarcomatoid hepatocellular carcinoma


Tumor microenvironment in giant cell tumor of bone: evaluation of PD-L1 expression and SIRPα infiltration after denosumab treatment

Programmed Death sentence examples within atezolizumab plus nab



First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.